Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Comment by double_from_hereon Apr 15, 2013 12:43pm
180 Views
Post# 21255280

RE: Mr. Todd Axelrod Proposition

RE: Mr. Todd Axelrod Proposition

As stated in the press release today:

"Collectively, these three nominees hold less than 1% of the shares of the corporation"

What this release doesn't state is what percentage Mr. Axelrod holds.

The current board will need to give me a better reason to vote against this proposal than their current press release.

Clearly, Mr. Axelrod's proposal has shaken the board up enough that they have today released more information about the on-going business then they have chosen to release in the last several years. That said, I still do not see anything here that gives me a clear vision of what they are doing to add to shareholder value.

If by voting for this proposal, we get more of this, then I will be voting in favour of these new directors.

I will now leave this in the hands of Dr. Yves Fradet and the other board members to give me a reason to stay the course. That course until now has taken us to FDA approval over a year ago and a share price that reflects something much different. The level of communication from the current board has been non-existant up until now and they appear to be taking steps to try and maintain that system.

I do not see any good reason to maintain the board in it's current state.

D_F_H

 

 

<< Previous
Bullboard Posts
Next >>